Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Schizophrenia01:17

Schizophrenia

974
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those...
974
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

250
Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...
250
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

626
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
626
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

619
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
619
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

473
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
473
Predicting Molecular Geometry02:27

Predicting Molecular Geometry

45.9K
VSEPR Theory for Determination of Electron Pair Geometries
45.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same author

[Mental diseases and driving ability-An update].

Der Nervenarzt·2026
Same author

A factor analytic comparison of three commonly used depression scales (HAMD, MADRS, BDI) in a large sample of depressed inpatients.

BMC psychiatry·2023
Same author

Parkinson and depression: review and outlook.

Journal of neural transmission (Vienna, Austria : 1996)·2022
Same author

Chronic vs non-chronic depression in psychiatric inpatient care - Data from a large naturalistic multicenter trial.

Journal of affective disorders·2021
Same author

Driving Performance Under Treatment of Most Frequently Prescribed Drugs for Mental Disorders: A Systematic Review of Patient Studies.

The international journal of neuropsychopharmacology·2021

Related Experiment Video

Updated: Feb 5, 2026

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia
13:08

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia

Published on: December 2, 2015

9.5K

Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone

Rebecca Schennach1,2, Michael Riedel1,3, Ilja Spellmann1,4

  • 1Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.

Pharmacopsychiatry
|September 21, 2018
PubMed
Summary

Most schizophrenia patients predicted high risk for antipsychotic nonresponse. Ziprasidone and haloperidol showed similar efficacy, but haloperidol caused more side effects.

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.2K
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

26.5K

Related Experiment Videos

Last Updated: Feb 5, 2026

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia
13:08

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia

Published on: December 2, 2015

9.5K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.2K
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

26.5K

Area of Science:

  • Psychiatry
  • Clinical Pharmacology

Background:

  • Assessing antipsychotic treatment response in schizophrenia is crucial.
  • Predicting nonresponse aids personalized treatment strategies.

Purpose of the Study:

  • Evaluate antipsychotic treatment response in schizophrenia patients stratified by predicted nonresponse risk.
  • Compare the efficacy and tolerability of ziprasidone versus haloperidol.

Main Methods:

  • Double-blind, randomized study of 112 schizophrenia patients.
  • Weekly assessments using PANSS, GAF, SOFAS, SAS, and HAS.
  • Patients categorized by predicted high/low risk of nonresponse.

Main Results:

  • 82% of patients were predicted to have a high risk of nonresponse.
  • No significant difference in PANSS improvement between ziprasidone and haloperidol for high-risk patients or the total sample.
  • Haloperidol showed significantly higher Simpson-Angus Scale (SAS) and Hillside Akathisia Scale (HAS) scores.

Conclusions:

  • A high proportion of schizophrenia patients face a significant risk of nonresponse to antipsychotic medications.
  • Ziprasidone and haloperidol demonstrate comparable efficacy, but haloperidol is associated with increased extrapyramidal side effects.